Furthermore, induction of miR-34a and subsequent SIRT1 inhibition induced DNA damage, shortened telomere length, and impaired telomerase activity, functions that could synergize with existing chemoradiation therapies.40 Given the results of these prior studies, SIRT1 has emerged as a promising therapeutic target to aid in the treatment of numerous cancers including GBM. The gene discussed is SIRT1; the disease is cancer.